<a href="https://laohu8.com/S/QTTB">Q32 Bio Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Reduces to $9.5M, EPS Improves to $0.78 Loss from $1.42 Loss in Previous Year
Q32 Bio Inc., a clinical stage biotechnology company, has released its financial results for the second quarter of 2025. The company reported cash and cash equivalents of $54.8 million as of June 30, 2025, which it expects to be sufficient to fund operations into 2027. The net loss for the three-month period ended June 30, 2025, was $9.5 million, compared to a net loss of $17.0 million for the same period in 2024. The reduction in net loss is reflected in a decrease in research and development expenses, which fell to $5.2 million from $13.4 million in the prior year, primarily due to lower bempikibart development costs and restructuring actions. General and administrative expenses also decreased to $4.0 million from $4.5 million, attributed to reduced headcount and legal costs. The company is continuing its development program for bempikibart, with patient dosing ongoing in the Part A open-label extension and Part B of the SIGNAL-AA trial. The topline data readout for Part B is on track for the first half of 2026. Additionally, Q32 Bio has appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to strengthen its leadership team.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE45091) on August 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.